Stock Ratings / Health Care / RKTO / earnings

LPCN (37) KTTA (44) DARE (44) HIND (35) ⌘ Pro Terminal →

Rocket One Inc. (RKTO) Next Earnings Date & Expected ±12.5% Move

$0.52 -4.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.51

Rocket One Inc. (RKTO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $12.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.51 (-1.08%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RKTO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY RKTO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.65-21.5% Next Q

Q2 (-2Q)

Grade D$0.51+7.8% Next Q

Q3 (-1Q)

Grade D$0.55-5.5% Next Q

Current

Grade D$0.52-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RKTO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RKTO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.55) forces dealer call-delta covering toward $2.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RKTO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RKTO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.07 Expected Swing

MODEL EARNINGS SETUP GAUGE

RKTO Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$12.5M	-$9.8M	52%
FY 2024	2024-12-31	$0	-$8.2M	-$7.0M	52%
FY 2023	2023-12-31	$0	-$8.1M	-$8.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RKTO)

✓Walkthrough of RKTO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RKTO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.67%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.52H $0.52L $0.47C $0.52VOL 331.4K

RES: $1.03SUP: $0.45SMA50: $0.66SMA200: $0.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RKTO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RKTO Butterfly Map → + Track RKTO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RKTO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RKTO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RKTO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RKTO)

Health Care Rank #524 of 1016 ⚔️ LPCN vs RKTO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RKTO vs. LPCN, KTTA, DARE, HIND)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rocket One Inc. (RKTO) ranks #524 by composite RQD confidence (44/100, grade D) and #871 by equity capitalization ($12.8M). Within this direct 5-issuer industry benchmark cohort, RKTO leads on earnings valuation at N/A trailing P/E, while RKTO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RKTO ACTIVE Rocket One Inc.	D	44/100	—	—	-35.0%	-4.96%	$12.8M	Benchmark Subject
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-rkto →
KTTA Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	/ktta-vs-rkto →
DARE Dare Bioscience Inc.	D	44/100	—	71.3%	-35.0%	+0.22%	$13.4M	/dare-vs-rkto →
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-rkto →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711786

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rocket One Inc. (RKTO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.5M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-40.5% YoY). On the balance sheet, RKTO closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$12.5M	-$9.8M	-$9.8M	$7.6M	—
FY2024 (FY)	2024-12-31	$0	-$8.2M	-$7.0M	-$7.0M	$7.7M	—
FY2023 (FY)	2023-12-31	$0	-$8.1M	-$8.4M	-$8.4M	—	—

3. RKTO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RKTO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rocket One Inc. (NASDAQ: RKTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.52 (-4.96% 1D, market cap $12.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RKTO ranks #524 in composite RQD confidence.

How does RKTO compare to LPCN and KTTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RKTO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LPCN (Lipocine Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and KTTA (Pasithea Therapeutics Corp.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, RKTO leads on earnings multiple (N/A) while RKTO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RKTO?

Per RKTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711786), Rocket One Inc. generated $0 in revenue, -$12.5M in net income, and -$9.8M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RKTO trading relative to its 50-day, 200-day, and 52-week technical levels?

RKTO last traded at $0.52 (-4.96% on volume of 131,506 shares), positioning the stock -21.21% below its 50-day simple moving average ($0.66) and -38.82% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.47 to $2.45, RKTO sits at the 2.5% percentile with a 14-day RSI of 33.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).